AU2020249493B2 - Combinations of iadademstat for cancer therapy - Google Patents
Combinations of iadademstat for cancer therapyInfo
- Publication number
- AU2020249493B2 AU2020249493B2 AU2020249493A AU2020249493A AU2020249493B2 AU 2020249493 B2 AU2020249493 B2 AU 2020249493B2 AU 2020249493 A AU2020249493 A AU 2020249493A AU 2020249493 A AU2020249493 A AU 2020249493A AU 2020249493 B2 AU2020249493 B2 AU 2020249493B2
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- cancer
- iadademstat
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382206 | 2019-03-25 | ||
| EP19382206.1 | 2019-03-25 | ||
| PCT/EP2020/058362 WO2020193631A1 (en) | 2019-03-25 | 2020-03-25 | Combinations of iadademstat for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020249493A1 AU2020249493A1 (en) | 2021-09-16 |
| AU2020249493B2 true AU2020249493B2 (en) | 2025-08-28 |
Family
ID=66175363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020249493A Active AU2020249493B2 (en) | 2019-03-25 | 2020-03-25 | Combinations of iadademstat for cancer therapy |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018083138A1 (en) * | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
-
2020
- 2020-03-25 EP EP20712594.9A patent/EP3946295B1/en active Active
- 2020-03-25 BR BR112021016171-6A patent/BR112021016171A2/pt unknown
- 2020-03-25 MX MX2021011610A patent/MX2021011610A/es unknown
- 2020-03-25 WO PCT/EP2020/058362 patent/WO2020193631A1/en not_active Ceased
- 2020-03-25 CN CN202080018266.2A patent/CN113573702A/zh active Pending
- 2020-03-25 PH PH1/2021/552326A patent/PH12021552326A1/en unknown
- 2020-03-25 CA CA3132473A patent/CA3132473A1/en active Pending
- 2020-03-25 CN CN202511368496.2A patent/CN121422229A/zh active Pending
- 2020-03-25 SG SG11202109025XA patent/SG11202109025XA/en unknown
- 2020-03-25 AU AU2020249493A patent/AU2020249493B2/en active Active
- 2020-03-25 KR KR1020217028840A patent/KR20210142614A/ko not_active Ceased
- 2020-03-25 JP JP2021557187A patent/JP7824627B2/ja active Active
- 2020-03-25 US US17/441,758 patent/US20220175698A1/en active Pending
-
2021
- 2021-09-13 IL IL286353A patent/IL286353A/en unknown
-
2026
- 2026-02-13 JP JP2026021790A patent/JP2026077769A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018083138A1 (en) * | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
Non-Patent Citations (1)
| Title |
|---|
| WANQIANG SHENG ET AL: "LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade", CELL, vol. 174, no. 3, 1 July 2018, pages 549-563 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113573702A (zh) | 2021-10-29 |
| JP7824627B2 (ja) | 2026-03-05 |
| SG11202109025XA (en) | 2021-09-29 |
| JP2026077769A (ja) | 2026-05-13 |
| KR20210142614A (ko) | 2021-11-25 |
| AU2020249493A1 (en) | 2021-09-16 |
| PH12021552326A1 (en) | 2022-06-27 |
| JP2022526525A (ja) | 2022-05-25 |
| EP3946295A1 (en) | 2022-02-09 |
| BR112021016171A2 (pt) | 2021-10-05 |
| CA3132473A1 (en) | 2020-10-01 |
| CN121422229A (zh) | 2026-01-30 |
| US20220175698A1 (en) | 2022-06-09 |
| WO2020193631A1 (en) | 2020-10-01 |
| EP3946295B1 (en) | 2026-08-05 |
| IL286353A (en) | 2021-10-31 |
| MX2021011610A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026077769A (ja) | 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 | |
| JP2019517549A5 (cg-RX-API-DMAC7.html) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| CN108295063A (zh) | 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂) | |
| WO2020187152A1 (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CA2984316A1 (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| JP2021514975A (ja) | サイクリン依存性キナーゼ阻害剤およびbet−ブロモドメイン阻害剤の組合せ | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| EP2841099A1 (en) | Combination of cd37 antibodies with bendamustine | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| EP3914257B1 (en) | Combination of a bcl-2/bcl-xl inhibitor with osimertinib | |
| RU2833564C2 (ru) | Комбинации иададемстата для лечения рака | |
| JP2017515843A (ja) | 抗egfr治療薬の投与量および投与 | |
| JP2023531090A5 (cg-RX-API-DMAC7.html) | ||
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| TW202045175A (zh) | Sumo-活化酶抑制劑及檢查點抑制劑之投與 | |
| AU2020278733A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| WO2023204259A1 (ja) | がんの治療又は予防用医薬 | |
| CN100553634C (zh) | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 | |
| CN114667159B (zh) | 喹啉衍生物与pd-1单抗的药物组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |